When to Order Imaging for Imaging of Invasive Breast Cancer: ACR Appropriateness Decoded

When to Order Imaging for Invasive Breast Cancer: ACR Appropriateness Decoded

A patient presents with a new biopsy-proven invasive breast cancer. The initial pathology report is on your screen, and now the crucial next step is staging. Do you need a breast MRI to define the local extent? What about a CT or PET/CT to look for distant disease? Ordering the correct initial imaging is critical for treatment planning, but ordering unnecessary studies can lead to delays, patient anxiety, and increased costs. This guide decodes the American College of Radiology (ACR) Appropriateness Criteria for imaging invasive breast cancer, providing clear, evidence-based recommendations to help you choose the right study for the right clinical scenario.

What Does ACR Imaging of Invasive Breast Cancer Cover?

This ACR guideline focuses on the appropriate use of imaging for the initial staging, post-treatment surveillance, and evaluation of suspected recurrence of invasive breast cancer. The recommendations are tailored to specific clinical contexts, including the initial clinical stage (e.g., early-stage vs. locally advanced) and the goal of the imaging study (e.g., evaluating locoregional vs. distant disease). The criteria cover common histologies like invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC).

These guidelines do not cover initial breast cancer screening, the workup of a palpable lump prior to biopsy, or the evaluation of ductal carcinoma in situ (DCIS) without an invasive component. The recommendations are designed for staging and follow-up after a definitive diagnosis of invasive cancer has already been established. For guidance on those topics, refer to the specific ACR criteria for breast cancer screening or evaluation of breast problems.

What Imaging Should I Order for Imaging of Invasive Breast Cancer? Recommendations by Clinical Scenario

The appropriate imaging pathway for invasive breast cancer depends heavily on the initial clinical stage and whether the goal is local staging, systemic staging, or surveillance.

For a newly diagnosed, clinical stage I-IIA (early stage) breast cancer, the focus is on locoregional evaluation. The ACR rates diagnostic mammography, digital breast tomosynthesis (DBT), breast ultrasound, and MRI breast without and with IV contrast as Usually appropriate. These studies help determine the extent of the primary tumor, identify multifocal or multicentric disease, and assess the contralateral breast. Ultrasound of the axilla is rated May be appropriate for nodal assessment. Importantly, for this same early-stage presentation, evaluation for distant disease is Usually not appropriate. Studies like whole-body bone scans, CT scans of the chest, abdomen, and pelvis, and FDG-PET/CT are not recommended due to the low pretest probability of finding metastatic disease.

When a patient presents with newly diagnosed, clinical stage IIB-III (late stage) breast cancer, the imaging workup is more extensive. For locoregional evaluation, breast MRI, mammography/DBT, and breast ultrasound remain Usually appropriate. However, axillary ultrasound and FDG-PET/CT also become Usually appropriate to assess nodal involvement and the primary tumor’s metabolic activity. For evaluating distant disease in these patients, systemic imaging is critical. FDG-PET/CT, CT of the chest, abdomen, and pelvis with IV contrast, and a Nuclear Medicine Bone Scan (Whole Body) are all considered Usually appropriate. This recommendation holds true for both ER+/HER2- subtypes and for more aggressive HER2+ or triple-negative cancers.

For surveillance after treatment, the recommendations diverge based on prior surgery and symptoms. For routine surveillance in an asymptomatic patient with a history of breast-conserving therapy (BCT), screening or diagnostic mammography/DBT is Usually appropriate. In contrast, for an asymptomatic patient after a mastectomy, no routine imaging is recommended; breast MRI is only rated as May be appropriate. Routine surveillance for distant metastatic disease in any asymptomatic patient is Usually not appropriate.

If a local recurrence is suspected based on symptoms or physical exam, the approach is different. In a patient with prior BCT, diagnostic mammography/DBT and breast ultrasound are Usually appropriate. In a patient with a prior mastectomy, ultrasound is the primary modality and is rated Usually appropriate. If distant recurrence is suspected due to new symptoms (e.g., bone pain, neurologic changes), targeted imaging is warranted. A Nuclear Medicine Bone Scan (Whole Body), CT of the chest, abdomen, and pelvis with IV contrast, FDG-PET/CT, and MRI of the head (for neurologic symptoms) are all Usually appropriate.

ACR Imaging Recommendations Table

Adult vs. Pediatric Imaging of Invasive Breast Cancer Imaging: Radiation Dose Tradeoffs

While invasive breast cancer is exceedingly rare in the pediatric population, the ACR provides pediatric-specific Relative Radiation Level (RRL) estimates for relevant imaging studies. This reflects the guiding principle of ALARA (As Low As Reasonably Achievable), which is paramount in younger patients due to their increased radiosensitivity and longer life expectancy, during which the potential effects of radiation exposure can manifest. For example, an FDG-PET/CT scan has an adult RRL of ☢ ☢ ☢ ☢ (10-30 mSv), but the pediatric RRL is also ☢ ☢ ☢ ☢, though with a lower typical dose range (3-10 mSv). This highlights that while the radiation category is high, protocols are adjusted to minimize dose for younger patients. Similarly, a whole-body bone scan is rated ☢ ☢ ☢ (1-10 mSv) for adults but ☢ ☢ ☢ ☢ (3-10 mSv) for pediatric patients, reflecting differences in tracer administration and metabolism. For non-ionizing radiation studies like ultrasound and MRI, the RRL is O (0 mSv) for all populations, making them preferable from a radiation safety standpoint when clinically appropriate.

Imaging Protocol Details for Imaging of Invasive Breast Cancer

Once you’ve decided on the right study based on the ACR criteria, ensuring it’s performed correctly is the next critical step. The specific imaging protocol—including MRI sequences, contrast timing, and nuclear medicine tracer dosage—can significantly impact diagnostic quality. Our protocol guides provide detailed, scannable references for the key studies recommended in these guidelines.

• MRI Breast With and Without Contrast
• Nuclear Medicine Bone Scan (Whole Body)
• CT Brain Without Contrast

Tools to Help You Order the Right Study

Navigating imaging guidelines can be complex, especially when dealing with nuanced clinical presentations. GigHz offers a suite of tools designed to support evidence-based clinical decision-making at the point of care.

For scenarios not covered in this article, the ACR Appropriateness Criteria Lookup tool provides a comprehensive, searchable interface to the full ACR guidelines, helping you find the right study for thousands of clinical variants.

To ensure technical excellence in the studies you order, the Imaging Protocol Library offers detailed, step-by-step protocols for a wide range of CT, MRI, and other imaging procedures, promoting standardization and quality.

When discussing the risks and benefits of imaging with patients, especially concerning ionizing radiation, the Radiation Dose Calculator is an invaluable resource. It helps estimate cumulative radiation exposure from various studies, facilitating informed patient consent and adherence to the ALARA principle.

Why is systemic imaging (like PET/CT) not recommended for early-stage (I-IIA) breast cancer?

For patients with clinical stage I or IIA invasive breast cancer, the probability of having distant metastatic disease at diagnosis is very low. Multiple studies have shown that the yield of systemic imaging in this population is minimal and does not outweigh the risks, which include radiation exposure, cost, and the potential for false-positive findings that lead to further unnecessary workups and patient anxiety. The ACR guidelines reflect this evidence by rating systemic staging studies as “Usually not appropriate” for this group.

What is the primary role of breast MRI in the initial staging of invasive breast cancer?

Breast MRI is the most sensitive imaging modality for detecting invasive breast cancer. Its primary roles in initial staging are to accurately define the extent of the known cancer, screen for additional unsuspected cancer in the same breast (multifocal/multicentric disease), and screen for cancer in the opposite (contralateral) breast. This information is crucial for surgical planning, helping surgeons decide between breast-conserving therapy (lumpectomy) and mastectomy. It is particularly useful for patients with dense breast tissue or in cases of invasive lobular carcinoma, which can be difficult to assess on mammography.

When should I order a bone scan versus a PET/CT for detecting bone metastases?

Both FDG-PET/CT and technetium-99m bone scans are rated as “Usually appropriate” for evaluating distant disease in patients with late-stage (IIB-III) breast cancer. FDG-PET/CT is generally more sensitive and specific for detecting both bone (osseous) and soft tissue (visceral) metastases in a single examination. A bone scan is highly sensitive for detecting osteoblastic bone metastases but does not evaluate soft tissues. PET/CT is often preferred as a single, comprehensive staging study. A bone scan may be considered if PET/CT is unavailable or contraindicated, or in specific cases of ER-positive cancers where bone-only metastases are more common.

Is routine imaging recommended for surveillance after mastectomy?

No. For an asymptomatic patient who has undergone a mastectomy, the ACR rates routine surveillance imaging of the chest wall (including mammography, ultrasound, or MRI) as “Usually not appropriate.” The primary method for detecting local recurrence after mastectomy is a thorough physical examination. Imaging is reserved for cases where there is a clinical suspicion of recurrence, such as a new palpable lump or skin changes.

Why is axillary ultrasound rated “May be appropriate” for early-stage cancer but “Usually appropriate” for late-stage cancer?

In early-stage (I-IIA) breast cancer, the likelihood of axillary lymph node metastasis is lower. While axillary ultrasound can be useful, its role is less established as a routine procedure for all early-stage patients, hence the “May be appropriate” rating. In late-stage (IIB-III) disease, the risk of nodal involvement is significantly higher, making axillary ultrasound a critical component of staging. Identifying suspicious nodes allows for ultrasound-guided biopsy, which can confirm metastasis and guide decisions regarding neoadjuvant chemotherapy and the type of axillary surgery needed (e.g., sentinel lymph node biopsy vs. axillary lymph node dissection).

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026